Therapy-related leukemia or myelodysplasia (t-leuk/MDS) is a serious problem that is increasing in frequency. We studied the clinical characteristics of 96 patients (pts) with a mean age of 48 years, and analyzed the molecular parameters that could predispose to t-leuk/MDS. Hematological malignancies were the most common primary (53%), followed by breast and ovarian cancer (30% combined). The mean latency until the development of t-AML was 45.5 months. Median survival was 10 months. Cytogenetics was abnormal in 89% of pts. FLT3 internal tandem duplications were found in six of 41 (14.6%) pts, of whom four had an abnormal karyotype. Analysis of drug metabolism and disposition genes showed a protective effect of the CYP3A4 1 n B genotype against the development of t-leuk/ MDS, whereas the CC genotype of MDR1 C3435T and the NAD(P)H:quinone oxidoreductase1 codon 187 polymorphism were both noncontributory. Microsatellite instability (MSI) analysis using fluoresceinated PCR with ABI sequence analyzer demonstrated that 41% of pts had high levels of MSI in four or more of 10 microsatellite loci. Immunohistochemistry demonstrated reduced expression of MSH2 and MLH1 in 6/10 pts with MSI as compared to 0/5 of pts without MSI. In conclusion, genetic predisposition as well as epigenetic events contribute to the etiology of t-AML/MDS.
Introduction
Therapy-related leukemia or myelodysplasia (t-leuk/MDS) is a worldwide problem of major proportions. Between 10-20% of acute leukemia patients reported in various series have developed the disease following previous therapy. 1 Studies of t-leuk/MDS from different countries reveal an increasing incidence, which is related to the widespread use of genotoxic therapies, as well as to the improved survival following treatment of the primary disease.
There have been many recent studies attempting to determine the etiology of t-leuk/MDS. The genetic pathways leading to therapy-related acute myeloid leukemia (t-AML) and t-MDS are complex, and multiple events are involved in which DNA damage from exposure to genotoxic stress leads to the secondary abnormalities that cause t-leuk/MDS. 2 Initially, studies focused on the 'extrinsic' events leading to t-AML/ MDS: the nature of the toxic exposures and the types of therapy preceding t-leuk/MDS (specific chemotherapy subtypes and/or radiotherapy). 3 More recently, studies have focused on the patient's intrinsic genetic makeup, which may predispose him to the development of t-leuk/MDS. These genetic factors can be subdivided into two groups: (1) genes involved in DNA repair (which directly prevent or reduce hereditable DNA damage which may be incurred during the administration of genotoxic treatments) and (2) genes involved in drug disposition and metabolism. The latter genes may prevent DNA damage by minimizing toxic exposure through removal and/or metabolism of harmful agents. The analysis of these genetic factors has been the subject of much recent study, since the ability to identify patients whose genetic makeup makes them prone to t-leuk/ MDS would enable planning treatment so as to minimize risk.
Much recent research has investigated the cellular mechanisms of DNA repair. The mismatch repair system (MMR), crucial for faithful replication of DNA during cell division, consists of a number of genes, seven of which have thus far been cloned and characterized. Defects in these genes result in the so-called 'mutator phenotype', which leads to the accumulation of mutations which may contribute to the development of t-leuk/ MDS upon exposure to genotoxic stress. 4 A number of studies, including our own, 5 have demonstrated that defects in DNA repair play a role in the predisposition to develop t-leuk/MDS. In recent years, technical improvements have enabled studying MMR with greater precision.
The uniformly poor prognosis of t-leuk is multifactorial in nature. In many cases the cells exhibit primary resistance to chemotherapy, which may be due in part to the expression of P-glycoprotein (P-gp), encoded by the multidrug resistance gene, MDR1. Another factor known to contribute to the poor prognosis of acute leukemia is the presence of FLT3 rearrangements (internal tandem repeats (ITD)). Previous studies have found FLT3 ITD to be rare in t-leuk/MDS. 2, 6 Here we present the findings of a series of 96 patients with t-leuk/MDS from a single institution. This series includes only patients who have been treated with chemotherapy, radiotherapy, or both, and does not include patients who developed secondary leukemia as part of the progression of MDS. We present here detailed clinical data and molecular analysis of factors contributing to predisposition and prognosis. We analyzed parameters contributing to poor prognosis, including karyotype, the presence of drug efflux activity, and FLT3 ITD. Furthermore, we analyzed some of the polymorphisms which are associated with altered activity of drug disposition genes (in CYP3A4, MDR1, and NAD(P)H:quinone oxidoreductase1 (NQO1)) to determine their influence on the propensity to develop t-leuk/MDS. Lastly, we have performed detailed studies of genetic instability and DNA repair genes to determine the role these mechanisms play in the predisposition to t-leuk/MDS.
Materials and methods
In all, 96 patients with t-AML or therapy-related MDS (t-leuk/ MDS) were treated at our institution between 1980 and 2003.
Clinical information was reviewed, including cytogenetics, treatment administered, and outcome. For cytogenetic analysis, BM aspirates were prepared according to the method of Michaeli et al 7 using conditioned medium derived from the human bladder carcinoma cell line 5637. G-banding was performed according to Klinger. 8 The clinical data of some of the patients in this series, 56 out of 96, were reported in our previous study, 5 in which different molecular parameters were investigated. The molecular studies were approved by the Hadassah Hospital Helsinki Committee.
All patients were analyzed for each of the various molecular parameters whenever the appropriate material required for each analysis was available. In all, 37 patients had fresh cells available and were analyzed for rhodamine efflux. Also, 22 were analyzed for microsatellite instability (MSI) and methylation-specific PCR (MSP), and 15 of these patients were analyzed by immunohistochemistry for MLH1 and MSH2. Analysis of FLT3, NQO1, CYP3A4, and MDR1 polymorphisms was performed on all patients for whom DNA was available.
DNA extraction
DNA was prepared for the various studies from leftover peripheral blood or bone marrow removed for diagnostic purposes. Mononuclear cells were isolated from peripheral blood and bone marrow aspirates by Ficoll-Hypaque density gradient centrifugation. DNA was extracted from mononuclear cells using a standard phenol-chloroform method. DNA was extracted from archived samples, in the form of paraffinembedded tissues and/or from buccal epithelial cells, using the 'QIAamp DNA Blood Mini Kit' (QUIAGEN, Hilden, Germany). Normal DNA samples were purchased from the National Laboratory for Genetics of the Sackler School of Medicine of Tel Aviv University, which has an ethnic groupspecific bank of anonymous normal DNA samples.
Functional P-gp expression
Functional MDR1 expression using rhodamine 123 efflux: Peripheral blood mononuclear cells were separated over Ficoll gradients and stained with rhodamine 123 using the method outlined by Chaudhary, 9 as described previously.
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FLT3 analysis FLT3 ITD rearrangements were analyzed as described by AbuDuhier.
10.
Drug metabolism and disposition genes CYP3A4: The A to G polymorphism (CYP3A4-V, also referred to as CYP3A4 1 n B) 11 was analyzed using PCR of a 321 bp segment of the 5 0 region of CYP3A4 extending into exon 1 nucleotide (nt À571 to À250). The PCR primers were designed to create a BamHI restriction site by inserting a 3 nt substitution in the reverse primer sequence such that the polymorphic nt (A to G) is the last of the 6 nt recognition sequence (CCTAGG) for BamHI. The polymorphism was then detected by restriction of the PCR fragment with BamHI. If the fragment was cut, the polymorphic sequence was present, and cutting to completion indicated homozygosity for the mutant sequence. The PCR primers, with the substituted nt's underlined in bold, are:
C3435T: The C to T polymorphism in exon 26 was analyzed as described by Cascorbi et al.
NQO1 polymorphism
The NQO1 C to T polymorphism at nt 609 was analyzed as described by Smith et al.
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MSI analysis
The detailed methodology of MSI analysis, bisulfite modification of DNA, and methylation-specific PCR of the promoters of: DNA repair genes (MSH2, MLH1), proapoptotic genes (BAX, p73), and of the ABL1 gene (which encodes a very active tyrosine kinase) are included in Supplementary Tables 1 and 2 , and the accompanying Supplementary Information, which describes the methods in detail.
Immunohistochemical analysis of DNA repair genes
Samples from 15 patients were studied for abnormalities in the level of expression of hMSH2 using immunohistochemistry performed on formalin-fixed, paraffin-embedded tissue sections. Immunostaining was performed according to the supplier's instructions of 'HistoMouse-SP Kit' (Zymed Lab Inc.) with mouse monoclonal antibody to hMSH2 (Ab-2, Oncogene Research Products, CALBIOCHEM, Cambridge, MA, USA) as per the manufacturer's instructions. Loss of MSH2 expression was noted as the absence of nuclear staining in neoplastic cells. Positively stained normal cells served as an internal control on each slide.
Statistical analysis
Statistical significance was determined using Fisher's exact test and Cochrane-Armitage trend test for polymorphisms, which were detected both in the heterozygous and homozygous forms. For polymorphisms present only in the heterozygous form, statistical significance was determined by w 2 , with Po0.05 being considered significant.
Results
Clinical data and outcome
Between the years 1980 and 2003, 96 patients with t-leuk/MDS were treated at the Hadassah Hospital. During the last 10 years, there has been a steep rise in the frequency of t-leuk/MDS such that over three-fold more cases were diagnosed between the years 1991-2000 compared with [1981] [1982] [1983] [1984] [1985] [1986] [1987] [1988] [1989] [1990] . This trend agrees with other reports stating that t-leuk/MDS is on the rise.
The mean age at diagnosis of the primary tumor was relatively young, 45 years (718, range 4-79). In all, 57% of the patients had an antecedent hematological malignancy. Hodgkin's disease and non-Hodgkin's lymphoma together represented 40%, 13% had myeloproliferative disease, and 4% had myeloma. Breast and ovarian cancer were common (30% combined), which explains the skewed sex ratio of the patients (F:M 55:41). Altogether, 46% of the patients had received . The mean time which elapsed from the end of treatment of the primary tumor until the development of t-leuk/MDS was 45.5 months (range 0-444 months). Nine patients developed t-leuk while still receiving therapy for the primary tumor for a total of 2-13 years. Overall, 67% of the patients developed the t-leuk/MDS with a short latency period, within 3 years.
In all, 66 patients had t-AML, 23 had t-MDS, and seven had a phenotype of t-ALL. Among the AML cases, M0 was the most common, seen in 31 patients, many of whom had prior MDS. There were seven patients with M1, four with M2, five with secondary APL, and 19 patients with M4 and M5.
Cytogenetic studies were performed on bone marrow specimens of 80 patients, of whom 71 (89%) had chromosomal aberrations. Supplementary Figures 1a and b show diagrammatically the types of aberrations found. Over half had a complex karyotype, while 27 (34%) of the patients had balanced translocations frequently involving chromosomes 1, 9, 11, and 17. This included t9;11 (characteristic of M5 t-leuk), t15;17 (APL), and inversion 16. Interestingly, 10 patients had translocations involving chromosome 1p. However, as seen in Supplementary Figure 1b , quantitative abnormalities were more common (60%), involving gains or losses of entire chromosomes or parts thereof, in particular, chromosome 7 or 5. Trisomy 8 was found in 13 patients. Combinations of these aberrations were detected in many patients.
The prognosis of our patients was very poor. The mean survival was only 10 months (range: 1 day to 168 months), which is similar to the survival reported in other series. Patients who underwent allogeneic BMT had a longer duration of survival, with a mean of 31 months (range 3-168 months). Only 10 patients are still alive 1.5-14 years (mean 4.6 years) since diagnosis, and four of these long-term survivors were transplanted.
Drug efflux as correlated with karyotype
In total, 37 patients were tested for rhodamine 123 efflux, a sensitive assay for drug resistance which is highly correlated with, if not completely specific for, P-gp activity.
14 Of these, 28 (76%) were positive for rhodamine efflux. This is virtually identical to the percent of P-gp-positive t-leuk patients (74%) reported by others. 15 As we reported previously, 5 all of our patients who were rhodamine-efflux negative had a unifying feature: they either had a normal karyotype or carried balanced translocations. This is in contrast to those who were positive for rhodamine efflux, who generally carried gains or losses of chromosomes.
FLT3 internal tandem duplications
In all, 41 patients were analyzed for FLT3 ITDs in exon 11. In six of these (14.6%), ITDs were detected. Interestingly, we treated one patient who had secondary APL following CLL. DNA from her peripheral blood at the time she had CLL had no abnormality of FLT3. However, an ITD is clearly detected in peripheral blood DNA at the time of transformation to APL ( Figure 1 , lanes 8A and 8B). Of six FLT3 ITD-positive patients, four had karyotypic abnormalities (two complex karyotype and two t-APL).
Drug metabolism and disposition genes CYP3A4-V: The A to G polymorphism was found in only 1/44 (2.2%) t-leuk/t-MDS patients analyzed. In comparison, we found heterozygosity or homozygosity for this polymorphism in 15% of the healthy Israeli population (Arabs and Jews, 20/134 individuals tested) (w 2 : Po0.025).
MDR1 C3435T polymorphism:
A total of 36 patients were analyzed for this polymorphism in exon 26 (Supplementary Figure 2) . Four out of the 36 (11%) of t-leuk/MDS patients were found to be homozygous for the putative protective C allele. In comparison, 14% of the normal Israeli population is homozygous for this allele. There was no difference in the number of chromosomes carrying the T allele (either in the heterozygous or homozygous state) between patients and 87 ethnic matched controls (Fisher's exact test, P ¼ 0.295 for TT and P ¼ 0.559 for CT). The controls included DNA samples from 33 Arabs and 54 Jews.
NQO1 polymorphism
In all, 46 patients were analyzed for the point mutation in codon 187, which has previously been reported to be associated with an increased tendency to develop AML and t-leuk. 16 We found that, of 46 patients, 15 were heterozygous and one was homozygous for the mutant allele (35% hetero-or homozygotes) (Supplementary Figure 3) . This was identical to the frequency of hetero-or homozygosity for the mutant allele seen in ethnic matched controls (150 Jews and 170 Arabs tested). Therapy-related leukemia D Rund et al
Analysis of MSI and loss of heterozygosity (LOH)
In all, 82 samples from 22 patients were analyzed for MSI using a panel of 10 microsatellite loci, which included six mononucleotide and four dinucleotide loci. Three loci, BAT26, BAT40, and BAT25, had been previously recommended for detecting MSI in colon carcinoma 17, 18 and have been reported to show clear-cut results. The other three were selected because of their location in the genes considered to play a role in the etiology of MSI. Thus, BAT13, a 13-thymidine mononucleotide repeat, is a monomorphic marker without any known allelic size variation, located upstream of the AG consensus sequence of the donor splice site of the first intron of the hMSH2 gene.
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BAT34C is a quasimonomorphic mononucleotide marker located in the 3 0 untranslated part of the exon 11 of the p53 gene, 20 which is known to play an important role in apoptosis. BAT16 is a mononucleotide quasimonomorphic marker consisting of 16 thymidine repeats in the sixth intron of the hPMS2 gene. 21 Microsatellite markers BAT26 (26 adenine repeats located within donor-acceptor sequence in the fifth intron of the hMSH2 gene) and BAT25 (25 thymidine repeats located within the 16th intron of the c-kit gene) were described as quasimonomorphic loci with allelic variation not exceeding two nt's, with one major allele for BAT26. 22 All the three microsatellites (BAT26, BAT25, and BAT16) are known to be of susceptible size variation in up to 95% of MSI-positive solid tumors and cell lines. 22 BAT40 is a polymorphic mononucleotide marker known to have 72% heterozygosity, 22 consisting of 40 adenine repeats and located in intron 2 of the 3-beta-HSD gene.
23 BAT40, BAT34C4, and BAT13 showed size variation in 95% of MSI-positive tumors. 22 Microsatellite locus D17S250 has been found to be unstable in MSI-positive cell lines. In contrast, no MSI was found in the D2S123 locus. 24 Four dinucleotide loci (Tp53, Rb intron 2, D2S123, and D17 S250) were previously found to be highly unstable in primary leukemia 25, 26 and t-leukemia patients. 27 In parallel, we examined the sensitivity of the automated fluorescence method for evaluation of MSI using a series of dilutions of Jukart cell line DNA mixed with buffy coat DNA of healthy individuals. Jukart cells have a heterozygous deletion of a G nt in the 8G monotract, located in the coding region of the BAX gene. We were able to discriminate one mutated allele diluted with three normal alleles (25%) by fluorescent-labeled PCR (data not shown). Table 1 shows the results of the various microsatellites analyzed for each patient. A high level of MSI (40% or more loci displaying instability) was observed in 9/22 patients (41%). A low level of MSI (between 20-40% of loci tested) was detected in 8/22 patients (36%). Five out of 22 patients (23%) did not show MSI. All patients with high and low levels of MSI showed instability in both type of markers. Dinucleotide markers presented instability in 29-48% (mean 41%) of cases, while mononucleotide markers showed instability in an average of 25%. Two of the mononucleotide markers showed a different pattern as compared to the other mononucleotide markers: BAT26 showed instability in one case (see Discussion) and BAT40 showed a very high level of MSI (68%), similar to that found for dinucleotide markers. Primary and second primary tumors from 12 patients were also available for MSI analysis. Four patients without MSI (microsatellite stable, MSS) were consistently MSS in the primary tumors. The other six patients with a high degree of MSI were also unstable in the corresponding primary tumors. One patient with MSI in 33% of loci studied had the same allele sizes in the samples of DNA prepared from his first and therapyrelated tumors. The remaining patient with instability in his second primary tumor and instability (1/7 loci, 14.2%) in his t-related leukemia sample also had LOH in p53 and D17S250 loci.
We were able to detect LOH in three dinucleotide loci: four patients had LOH in the D2S123 locus; two patients had LOH in the p53 locus; and two others had LOH in the D17S250 locus. In summary, we found LOH in t-leuk/MDS samples from seven different patients: six in one locus and one in two loci (Table 1) .
Representative ABI377 profiles are shown in Figure 2 . In all cases, germline DNA was used for comparison and, in some cases, multiple samples were available of cells prior to and following chemotherapy. PCR products displaying peaks in addition to the germline allele peaks, or replacing germline peaks, demonstrate the presence of MSI.
hMSH2 protein expression
Considering the probability of a progressive decrease in MMR system efficiency, we looked for possible changes in hMSH2 protein expression during MDS or transformation to t-leuk/MDS. The expression of the mismatch repair protein hMSH2 was analyzed using immunohistochemistry. Samples of 15 patients were analyzed, of which six had MSI. Four out of these six MSI patients showed reduced expression of MSH2 as compared to 0/9 patients without MSI (Figure 3 ).
Promoter methylation of DNA repair and tumor suppressor genes
Methylation status of the promoters of hMSH2, hMLH1, p73, BAX, and ABL1 genes was analyzed in 40 DNA samples (representing primary tumors, remission, and t-leukemia samples) from 13 patients with t-AML. DNA samples were analyzed by methylation-specific PCR. No methylation was found in the promoters of the hMSH2, hMLH1, p73, and BAX genes in the t-leuk/MDS patients (data not shown).
To ensure that the lack of methylation did not result from insufficient sensitivity of the methodology, we investigated the methylation status of the promoter of these genes in 19 cell lines. Promoter methylation was frequently observed. In five out of 19 cell lines, methylation was found in the hMLH1 gene, in three out of nine cell lines there was methylation of the p73 gene, and in three out of 18 cell lines the ABL promoter was methylated. No methylation was found in the hMSH2 and BAX genes in any of the cell lines studied (data not shown).
Promoter methylation of the ABL1 gene
A total of 40 DNA specimens (derived from 22 paraffinembedded tissues and 18 peripheral blood and bone marrow samples) of 13 patients was studied for ABL1 promoter methylation. These included samples of 11 of the primary tumors, 11 blood or bone marrow samples at remission, and 18 samples with t-leuk/MDS. Methylation status of the ABL1 Figure 2 ABI analysis of MSI. Representative analyses of three representative microsatellite loci performed on DNA isolated from diagnostic specimens taken from patient 7 over a 6-year span. Each panel (labeled 1-4) demonstrates a different tissue analyzed for a specific microsatellite. (For a complete list of miscrosatellites analyzed see Table 1 , which is included in the Supplementary Information) Panels numbered 1 represent peripheral blood, at the time of diagnosis of low-grade NHL in leukemic phase (BCL2 positive). Panels numbered 2 represent the bone marrow, at relapse of low-grade NHL after chemotherapy. Panels numbered 3 represent the bone marrow, showing MDS transforming to t-leuk. Panels numbered 4 represent the normal lung tissue from bronchoscopic biopsy.
(a) Represents analysis of the BAT40 locus, (b) represents the RB2 locus and (c) demonstrates the p53 locus. At the time of diagnosis, all the three loci show clear heterozygosity. Over time, new alleles were detected in all loci, which demonstrate the presence of genetic instability following cytotoxic therapy and disease progression.
Therapy-related leukemia D Rund et al promoter was studied using MSP followed by restriction enzyme analyses. The results are shown in Table 2 . Six patients (46%) were found to have ABL1 promoter methylation in the primary or secondary malignancy. No methylation of the ABL promoter was found in normal tissues or during remission. Of note, no methylation of the ABL promoter was found at the time of the development of t-leuk/MDS, with the exception of three patients (two with t-APL and patient 7, see below).
Interestingly, of all the cases of t-leuk/MDS analyzed, only in the two cases of t-APL ABL promoter methylation was found. In both of these patients, the remission marrow showed no methylation. In contrast, we studied eight pts with primary APL, and no ABL promoter methylation was observed (data not shown). Of note, complete methylation was found not only of the ABL1 promoter region but also of the two first CpGs of exon 1a. By way of comparison, we examined 24 DNA samples prepared from the peripheral blood of healthy individuals (aged 25-70 years) for ABL promoter methylation status. Methylation was found in four out of 24 individuals (16.6%). Three of the individuals with such methylation were over 65 years old, and one was 35 years of age. The region found to be methylated covered only the complete promoter region, but not exon 1a, which was methylated only in the 2 t-leuk APL patients and in one other patient (patient 7; Figure 4 ). Patient 7, who was diagnosed as having BCL2-positive NHL (December 1993), was found to have ABL exon Ia methylation. At the time of diagnosis, simultaneous BM and lymph node samples showed methylation of the promoter region and also of the two first CpGs of exon Ia. The peripheral blood sample prepared simultaneously (which was also BCL2 positive by PCR) did not show methylation. Two years later (December 1995), methylation (promoter and first exon) was still present in his BM sample, which was infiltrated with small-cell lymphocytic lymphoma (data not shown). At 3 months (March 1996), after treatment, when the patient was in remission from NHL, no methylation was observed in the BM and he underwent autologous BMT. After 2 years (March 1998), the bone marrow showed t-MDS in addition to minimal amounts of residual lymphoma, and the same pattern of methylation was observed in the promoter and exon 1a (Figure 4 ). After 8 months, following allogenic BMT, the BM sample which had a fully female (donor) karyotype, the promoter region of ABL1 gene, was unmethylated.
Discussion
Recently, t-leuk/t-MDS has been found to be an increasing problem worldwide, in part due to improved survival rates following primary malignancies. 3 Many studies have addressed various aspects of the t-leuk/MDS problem, but, to our knowledge, this study is one of the largest which addresses not only the clinical but also the genetic, epigenetic, and molecular Figure 3 Immunohistochemistry of hMHS2. Normal bone marrow and t-leuk bone marrow paraffin sections were stained for hMSH2 expression. In the panel at the left, positive staining (numerous cells stained dark red) is seen in normal bone marrow, as compared to virtually absent staining in t-leuk bone marrow. (Colour version of the figure available online.) Table 2 ABL1 promoter methylation analysis Remission BM after alloBMT with full donor engraftment.
Therapy-related leukemia D Rund et al aspects of this disease in a single group of adult patients. In our earlier study, 5 we found that p53 mutations and MSI were a hallmark feature of t-leuk/MDS. In the current study, we investigated the presence of MSI using a more reliable method, as well as studying other molecular parameters that could lead to t-leuk/MDS (predisposing polymorphisms and aberrant methylation).
Clinical and prognostic parameters
The incidence, types of previous malignancies, prior therapy, karyotypic abnormalities, and outcomes of our patients were very similar to those in other series of adult patients. 28 The latency until the development of t-leuk/MDS in our patients was virtually identical to that in other series, and was much shorter after topo II inhibitors than after alkylating agents. 2, 29 A major difference in our series is the age of the patients. Our patients developed their primary tumor at a mean of 45 years of age and t-leuk/MDS developed at a mean age of 48 years. Other series have reported the mean age of t-leuk/MDS to be older. 28, 30 The poor outcome of our relatively young patients led us to investigate factors that affect remission rates. Most patients were positive for the drug resistance phenotype demonstrated by rhodamine efflux. In addition, we investigated FLT3 ITD rearrangements, since these are an important prognostic parameter, and have been reported at variable frequencies in t-leuk/t-MDS. 6, 31 Although reported to be frequent in MDS which transformed to AML, 32 FLT3 ITD have been reported to be uncommon (only 3.4%) in t-leuk. 6, 31 Among our patients, a significant percent (14.6%) were positive for FLT3 ITD. This is a lower percent than that found for our primary AML patients, of whom approximately one-fourth have FLT3 ITD (Cohen and Rund, unpublished data). Furthermore, four out of the six FLT3 ITD-positive patients had an abnormal karyotype, including two with complex karyotypic changes and two with secondary APL, in contrast to one published series which found FLT3 generallly in t-leuk cases with a normal karyotype. 31 Predisposing genetic factors Drug-metabolizing and disposition genes: The young age of our patients led us to examine various genetic factors which could predispose to the development of t-leuk/MDS, including drug-metabolizing and disposition genes. One of the first such polymorphisms to be studied, located in the 5 0 region of the promoter of the CYP3A4 gene, 11 was found to decrease the risk of t-AML in pediatric patients. Recent studies have not confirmed this finding in children, 33 and this polymorphism has not been extensively studied in adult t-AML. Our results demonstrated that only 2.2% of our adult patients carried the 'protective' C polymorphism, compared to 15% of Israeli normal controls. This finding suggests that this polymorphism indeed is an important protective element in adult t-leuk/MDS. Larger studies in other populations need to be performed, since the frequency of this polymorphism varies in different populations (for instance, it is not found in Japanese). 34 It has recently been reported that a C to T polymorphism in the MDR1 gene at position 3435 is associated with increased activity of the gene product, P-gp. 35 This polymorphism may reduce genetic susceptibility to various malignancies, since the C allele lowers effective exposure to genotoxins. It was found that the presence of the T allele is a risk factor for the development of renal epithelial tumors. 36 Interestingly, this polymorphism has also been found in colorectal tumors with a high degree of MSI, but not in those without MSI. 37 The 'protective' C allele was common in the Israeli population, with 14% of normal Israelis being homozygous for this allele. We found no difference in the percent heterozygosity or homozygosity for the C allele when comparing controls to normals of the same ethnic groups.
In contrast to other studies, 16, 34 we did not find an increase in the frequency of the null allele of the NQO1 gene in our t-leuk/ MDS patients compared to normals of the same ethnic groups. One study in pediatric patients also did not find an association of the null allele with t-AML. 33 MSI and DNA repair MSI as a manifestation of mutator phenotype has been well documented in many solid tumors, but data on the level of MSI in t-leuk/MDS are controversial. Earlier studies including our own 5 used polyacrylamide gel electrophoresis of radioactivelabeled PCR products, which could yield ambiguous results. The Figure 4 Sequence analysis of methylation-specific PCR. DNA samples of patient 7 were modified by bisulfite (such that all unmethylated Cs are transformed to Ts and only methylated Cs will appear in the sequence) and methylation-specific PCR of the ABL gene was performed. Lanes in section 1 represent DNA isolated from peripheral blood at the time of diagnosis, section 2 represents the LN biopsy at diagnosis, and section 3 represents BM at the time of t-MDS transforming to leukemia. Note that in section 1, the lane labeled C has no bands, whereas in section 2 faint bands seen (between the asterisks). These bands are seen more strongly in section 3.
Therapy-related leukemia D Rund et al methodology used in this study is more precise. Our current study showed 41% MSI overall, which, while lower than our previous results, is similar to the percent found by others. For instance, a significant incidence (44, 47 , and over 60%) has been reported. [38] [39] [40] Casorelli, who found over 60% MSI, studied four of the same loci which we used, 40 and this study also found a significant relationship between t-AML and the type of treatment administered (greater with chemotherapy than radiotherapy). This study also found MSI to be common in t-APL (3/5, 60%) in contrast with 0/8 de novo APL cases. Other studies with smaller numbers of t-leuk patients found them to frequently have MSI. 25, 38 At the opposite extreme, Rimsza et al 41 did not observe MSI in any leukemia patients, including 62 secondary leukemia patients (which included both t-leuk and leukemia following MDS), whose mean age was 63 years. Besides methodological differences and differences is age, another reason for these conflicting results may be the absence of a consensus panel of microsatellite loci for leukemia. Boyer et al 42 studied 14 patients with t-leuk/MDS and found essentially no MSI, with a panel of 14 microsatellites that included BAT25 and BAT26. However, all other miscrosatellites which Boyer studied were different from the ones studied by us. Furthermore, in Boyer's study, only five t-MDS were studied for BAT26, and only one of the t-leuk patients we studied showed MSI at this locus. Recently, Faulkner 43 suggested the need for a consensus panel of loci. However, in contrast to his reported findings, 43 we frequently found MSI at the BAT25 locus (23%). BAT40, which Bacon et al 44 reported to be hypermutable in sperm cells, 44 was the locus with the most MSI in our patients (68%). Others have not found MSI at this locus 41 or have found it in a smaller percentage of patients (19%). 43 The absence of changes in BAT34C4 locus, which is located in the 3 0 region of the p53 gene, may indicate its important role in maintaining mRNA stability of the gene. Clearly, additional studies are needed in this area.
Our original hypothesis suggested that the mutator phenotype in patients with t-AML/MDS might have contributed to the development of both the primary malignancy and the treatmentrelated one. 5 Subsequent studies have suggested as well that this may be the case. Indraccolo et al 45 suggested that microsatellite alterations could be used as a marker of disease progression in the development of t-leuk/MDS. Similarly, Olipitz found that three out of four MSI pts positive for MSI in their t-leuk/MDS were also MSI positive in their primary tumors. 26 Our current data confirm these findings. In some cases, we found that the same molecular alteration was found in the primary and subsequent malignancies, but was not present in the remission samples (data not shown). We also found MSI in different tissue samples of the same patient within a short period of time. It is possible that the observed MSI may be a result of unrepaired changes in DNA that occurred during and/or immediately after therapy. Our findings in patient 7 are consistent with this hypothesis. In addition, similar to the findings of Olipitz, 26 we have also found some MSI-positive patients with the identical MSI profile in the primary tumor and the t-leuk sample, which differed from the microsatellite profile of their normal or remission tissues (not shown).
Mutator phenotype suggests a deficiency in activity of the MMR genes. Germline mutations in hMLH1, hMSH2, hMLH3, and hPMS2 have been found in a wide spectrum of primary malignances. Recently, MSI was reported in two leukemia cell lines, both of which had defective expression of hMSH2 and one had a point mutation in exon 13 of the hMSH2 gene. 46 More recently, Zhu et al 25 found abnormal expression of the hMSH2 gene in 32.6% (14/43) of patients with adult AML, including one case of ALL and two cases of t-AML. One patient with t-AML showed lack of hMSH2 expression. LOH at the hMSH2 locus was found in five of 11 cases examined.
These findings prompted us to study the hMSH2 protein in our t-leuk/MDS patients. In four of six MSI-positive cases, reduced hMSH2 protein was found compared to normal hMSH2 protein in all of the nine patients without MSI. These data suggest a role of the hMSH2 protein in the MSI phenotype. A variant hMSH2 allele was recently found to be over-represented in t-leuk cases. 47 Epigenetic events: methylation of promoters of tumor suppressor and DNA repair genes Therapy-related-leukemia patients have a high incidence of non-germline mutations in the p53 gene, 5 as well as an increased MSI progressing with the disease. These characteristics allowed us to suggest that a possible epigenetic mechanism causing these changes might be methylation of the promotor region of the relevant genes. It is well known that methylation of the promoter region occurs in tumor suppressor genes and of the hMLH1 gene in many solid tumors, but this has been studied less often in t-leuk/MDS. Up to 58% of t-leuk patients have methylation of p15. 48 Methylation of p16 has been reported less frequently in t-leuk, but p14 is never methylated.
48,49 DAP kinase (a proapoptotic gene) was aberrantly methylated in 48% of t-leuk samples, with associated diminished expression. 50 We did not find methylation in the promoters of hMSH2, hMLH1, p73, or BAX in t-leuk/MDS patients, although we found it in hMLH1 and p73 in a number of cell lines. This is similar to the findings of Sheikhha et al, 39 who found MSI but not hypermethylation of mismatch repair genes in t-leuk/MDS. Seedhouse 51 also found no methylation of DNA repair genes in t-leuk. Casorelli 40 reported promoter methylation of hMLH1 in 6/25 t-leuks including 3/3 t-APL cases, in contrast with 0/8 cases of de novo APL. Interestingly, we found only ABL to be methylated in 6/18 t-leuk patients. ABL is a tumor-suppressor gene, acting indirectly through p53, p73, and other proteins.
52,53 ABL methylation was not uncommon; in addition to the two cases of t-APL, it was also found in normals (mostly elderly), 54 though we did not find it in de novo APL. In most cases only the promoter region was methylated, but in some exon 1a was also methylated. The functional consequences of these epigenetic changes remain to be explored.
In conclusion, t-AML and MDS is an increasingly frequent, devastating clinical problem with a complex, multi-step pathogenesis. Genotoxic stress (chemo-or radiotherapy), combined with genetic makeup (with variation in drug metabolism/ disposition genes) and further epigenetic events, all combine to cause this serious complication of successful therapy. Additional studies of the genetic factors which predispose to the development of t-leuk/MDS will allow, in future, identification and selection of patients who may require novel treatment strategies to prevent this complication. support of the Gabriella Rich Foundation and the Caesaria Edmond Benjamin De Rothchild Foundation.
